Blog
RSS FeedPosted by Michael Wonder on 17 Oct 2016
Emtricitabine/rilpivirine/tenofovir alafenamide in HIV: added benefit not proven
17 October 2016 - Research questions on adolescents not investigated/evidence on components not simply transferable to the combination. ...
Posted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 04 Oct 2016
Crizotinib in NSCLC: new data are inconclusive
4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue. ...
Posted by Michael Wonder on 04 Oct 2016
Ibrutinib in CLL: no additional clinical benefits for treatment-naïve patients
4 October 2016 - The dossier contains no suitable data on first-line use. ...
Posted by Michael Wonder on 26 Sep 2016
Nivolumab plus ipilimumab in melanoma: added benefit in certain patients
15 September 2016 - Survival advantage in BRAF V600 wild type tumour depends on gender / severe side effects more common. ...
Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
Posted by Michael Wonder on 17 Sep 2016
Selexipag in pulmonary arterial hypertension: additional clinical benefit is not proven
16 September 2016 - Limited comparator therapy and division of population inadequate/the only study compared the medicine with placebo. ...
Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects. ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...
Posted by Michael Wonder on 07 Sep 2016
IQWiG Autumn Symposium 2016: programme is now online
6 September 2016 - More light than shadow? Beneficial and hindering factors for successful clinical studies. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 17 Aug 2016
German body calls for pause in European plan for fast track drug approval
16 August 2016 - Plans by the European Medicines Agency to expand its fast track approach to approving new drugs have ...
Posted by Michael Wonder on 16 Aug 2016
German agency criticizes European program for speeding some drug approvals
15 August 2016 - in pointed remarks, Germany’s cost-effectiveness watchdog has criticized an effort by European regulators to accelerate approval ...